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tation of both IL-12 and regulatory DC to suppress GVHD.440
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We have previously shown that inhibition of the MEK
pathway with selumetinib greatly reduced T cell prolifera-
tion induced by allo-DC stimulation with minimal loss in
virus-speciﬁc cytokine production in EBV and CMV-stimu-
lated T cells in vitro, and that selumetinib signiﬁcantly
reduced GVHD and increased survival in a GVHD mouse
model. Thus, MEK inhibitors represent a novel class of
immunosuppressive agents that potentially target GVHD
initiation while sparing beneﬁcial immunity in the allo-SCT
setting. We sought to determine if trametinib, a recently
FDA-approved MEK inhibitor based on clinical responses inFigure 1
Figure 2the melanoma setting, would also demonstrate selective
inhibition of alloreactivity while preserving virus-speciﬁc
immune function. In 6 allo-DC/responder PBMC pairs, we
assessed the dose response of inhibition of proliferation by
trametinib, and found similar dose response patterns to
selumetinib with w50% inhibition of alloreactivity at the 1
mM dose and nearly complete inhibition at 10 mM (Figure 1).
As previously reported with selumetinib, the percentage of
polyfunctional CMV and EBV-stimulated PBMC capable of
producing IL-2, IFN-g, TNF-a or MIP1-b was unchanged by
exposure to MEK inhibition (n¼4, CMV pp65 peptide re-
sponses shown in Figure 2). While the overall fraction of
functional responding cells to virus did not change in
response to MEK inhibition, TNF-a production was reduced
at higher doses of both trametinib and selumetinib. Further
experiments are planned, both in vitro and in animal models,
to conﬁrm the potential utility of this class of drugs to reduce
GVHD while preserving virus-speciﬁc T cell function in the
allo-SCT setting.441
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Introduction: Cannabidiol (CBD), a safe and non-psycho-
tropic ingredient of marijuana, has been shown to exhibit
potent immune-modulatory and anti-inﬂammatory proper-
ties in animal models of various inﬂammatory diseases. We
have recently presented data suggesting that the combina-
tion of CBD with standard GVHD prophylaxis is a safe and
promising strategy to reduce the incidence of GVHD. We
herein update the data in a larger cohort, analyzing both
short and long term transplantation outcomes.
Methods: We conducted a phase I/II trial. All patients were
given standard GVHD prophylaxis consisting of cyclosporine
and short course methotrexate. CBD was orally administered
at a dose of 150 mg twice daily from starting of conditioning
up to day +30. We sequentially monitored a panel of 4 serum
cytokines (soluble TNF receptor 1 (sTNFRI), soluble IL-2 re-
ceptor alpha (sIL2R-alpha), hepatocyte growth factor (HGF),
and IL8)). Blood samples were taken at days -7(A), 0(B),
+14(C), and +28(D). We assessed the difference in blood
levels between the various time points (B-A, C-B and D-C).
Results: Between 9/2012 and 10/2013, 34 consecutive pa-
tients with hematological malignancies undergoing alloge-
neic transplantation were enrolled (median age¼52, range,
22-71 years). Most patients had acute leukemia/MDS (n¼28).
Most (73%) were in CR/PR at transplantation. Majority
(n¼26) of patients were given a myeloablative conditioning.
The donor was either a HLA identical sibling (n¼17), a 10/10matched unrelated donor (n¼14) or 1 antigen mismatched
unrelated donor (n¼3). All patients were given G-CSF
mobilized peripheral blood stem cell grafts. Median follow-
up was 8 months (range, 3-13). There were no grade 3-4
toxicities attributed to CBD. There were no cases of graft
rejection. Cumulative incidences of grade 2-4 and 3-4 acute
GVHD by day +100 were 15% and 7%, respectively. Cumula-
tive incidences of overall and extensive chronic GVHD at 12
months were 41% and 12%, respectively. Cumulative in-
cidences of relapse, NRM and OS at 12 months were 27%,
16.5% and 71%, respectively. Patients with increased D-C
serum levels of IL8 and sIL2R-alpha had a relative risk of 3.8
(95% CI .8-17.1, p¼.1) and 2.8 (95% CI 1.1-7.5, p¼.05),
respectively, for developing chronic GVHD.
Conclusion: Combination of CBD with standard GVHD pro-
phylaxis is a safe and promising strategy to reduce the inci-
dence of GVHD. Further studies comparing this novel
approach with standard GVHD prophylaxis are warranted.442
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Acute graft-versus-host disease (GVHD), one of the major
complications associated with allogeneic blood and marrow
transplantation (BMT), develops primarily in the skin, liver,
gastrointestinal tract and lymphoid tissues of patients who
receive this therapy for various hematological malignancies.
The homing of T cells to GVHD target organs and their
regulation via integrins, selectins and chemokine receptors
have been recognized as potential novel realms for inter-
vention to ameliorate or prevent GVHD while still allowing
the beneﬁcial graft-versus-tumor effects. A number of
studies have shown that transplantation of donor T cells
lacking beta7; a chain of the intestinal homing receptor
alpha4beta7 integrin, was effective at ameliorating GVHD in
BMT murine models. Likewise the use of monoclonal anti-
body against the alpha4 or the beta7 subunits have been
alluded to as potential treatments for intestinal bowel dis-
ease and GVHD, and trials, at least for the former, have been
initiated in the clinic. Here we investigated an alternative
method to block alpha4beta7 expression on donor T cells in
order to impair their capacity to inﬁltrate gut tissue in a
murine BMT model, using antisense morpholino oligonu-
cleotide (AMO) technology (Gene Tools, LLC). Electroporation
of donor T cells permitted a greater than 90% transfection of
AMO and an average 82.265.78% knockdown on alpha4-
beta7 expression, just 24 h after treatment with trans-
lational-blocking AMO targeting the mouse beta7 chain.
Beta7 expression ¼ 84.355.30% in electroporation control
cells vs. 41.656.77% in AMO treated cells (50.627.85%
decrease), and a4b7 expression ¼ 23.07.40% in electropo-
ration controls cells vs. 4.11.91% after AMO treatment. In
the MHC-haploidentical C57BL/6 (B6) into (B6xDBA/2)F1
[H2b/d; B6D2] BMT murine model, B6D2 mice challenged
with 3x106 AMO-treated (50 mM) B6 T cells had a MST of 20
days vs. a control group given untreated/electroporated
donor T cells (MST 14 days; p<0.01). This signiﬁcant pro-
longation of survival correlated with a signiﬁcant decreased
inﬁltration of donor eGFP+B6 T cells into intestinal tissues as
measured by histological analysis (p ¼ 0.024). This data
strongly suggested that silencing beta7 on donor T cells with
AMO technology, albeit transiently as done here, could be
